[walnutclosefarm]

> Mounjaro is not an obesity drug. It's a type 2 diabetes drug. Do not call it an obesity drug

This is an absurd argument. It's a drug. It has specific metabolic affects in humans that are valuable to people's health, among which are the control of blood glucose levels, and control of appetite and nutrient uptake, leading to loss of excess weight. That it is currently labeled only for Type 2 diabetes is a marketing decision by the manufacturer, not a characteristic of the drug.

Or, to put this another way: the drug is doing exactly the same thing whether you measure its effectiveness with a glucometer, or with a bathroom scale.

[bedast]

> That it is currently labeled only for Type 2 diabetes is a marketing decision by the manufacturer, not a characteristic of the drug.

Regulatory approval. It is a diabetes drug because it has been evaluated as such, including understanding the primary effects and side effects at various dosing levels. Mounjaro is prescribed to diabetics from 2.5mg to 15mg in increments of 2.5mg and titrated based on needs and goals.

Typically, weight loss versions of these drugs (Saxenda and Wegovy) are dosed higher than their diabetes counterpart, and are just titrated to maximum dose over time to maximize weight loss benefits. So evaluation is based on this, and approval follows this.

Various drugs do get used for off-label purposes, but the drug makers can't promote this because their marketing claims are regulated. This is why the coupon terms were changed.

[runnerup]

Tirzepatide will have FDA approval for obesity this year. GP’s dogmatic stance that “Mounjaro is not an obesity drug!!” is overwhelmingly rejected by the available evidence.

[mannanj]

Coupon terms changed because drug makers can't promote this? Can you help me understand why the ability to promote would have any bearing on a coupon's terms?

[bedast]

Allowing the coupon to be used for the treatment of obesity is an implicit approval for the drug to be used in this way, and coupons are a form of marketing. Lilly cannot approve nor market this drug in a way that is off-label. This is why when Lilly talks about testing tirzepatide for weight loss, they say tirzepatide and not Mounjaro. Whenever you see articles mentioning Mounjaro for weight loss, these are statements not originating from Lilly.

[MichaelZuo]

Coupons for products or services are considered a form of promotion.

[runnerup]

Mounjaro will have FDA approval for obesity this year. GP’s dogmatic stance that “Mounjaro is not an obesity drug!!” is soundly rejected by the available evidence.

[bedast]

Mounjaro will never be approved for obesity. The documentation for dosing is for diabetes. If the trend follows with how Novo Nordisk has released their versions of this, dosing for weight loss will be different than dosing for diabetes care, and so it must be under a whole new label.

Mounjaro is a trade name for a diabetes drug and that won't change. So no, it is not soundly rejected.

It's not as simple as "SQUIRT JUICE INSIDE ME GET THINNER AND CURE DIABETES". There's a lot more to this than you seem to understand.

[m348e912]

>It's not as simple as SQUIRT JUICE INSIDE ME GET THINNER AND CURE DIABETES

It kind of is that simple. Tirzepatide has three main functions: Hunger suppression, slower digestion, and increased insulin sensitivity.

For a large portion of people who are overweight, this will get them thinner and in some cases reverse t2 diabetes.

[BoorishBears]

Sometimes you need to examine subtext a little closer.

Obviously this person is (reasonably) upset* that off-label use is muscling out on-label use, when the two uses are of two very different classes.

Their issue isn't just the fact that the common vocabulary has switched to focusing on weight loss, it's the general shift in where the supply is going that's accompanies said shift in vocabulary

Being overweight is a serious health issue, but Type 2 diabetics were using it in a way that was much more acutely pressing, with much fewer alternatives. It's not hard to understand why diabetics would feel upset/threatened by a secondary off-label use of such a different class.

* I read it as upset as the situation, not at those who are overweight to be clear